These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 14714403)

  • 1. Archaeobacterial ether lipid liposomes as vaccine adjuvants.
    Sprott GD; Patel GB; Krishnan L
    Methods Enzymol; 2003; 373():155-72. PubMed ID: 14714403
    [No Abstract]   [Full Text] [Related]  

  • 2. pH-sensitive liposomes as adjuvants for peptide antigens.
    Chang JS; Choi MJ
    Methods Enzymol; 2003; 373():127-36. PubMed ID: 14714401
    [No Abstract]   [Full Text] [Related]  

  • 3. Liposomal cytokines and liposomes targeted to costimulatory molecules as adjuvants for human immunodeficiency virus subunit vaccines.
    Ozpolat B; Lachman LB
    Methods Enzymol; 2003; 373():92-100. PubMed ID: 14714398
    [No Abstract]   [Full Text] [Related]  

  • 4. Cationic liposomes as vaccine adjuvants.
    Christensen D; Korsholm KS; Andersen P; Agger EM
    Expert Rev Vaccines; 2011 Apr; 10(4):513-21. PubMed ID: 21506648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs.
    Felnerova D; Viret JF; Glück R; Moser C
    Curr Opin Biotechnol; 2004 Dec; 15(6):518-29. PubMed ID: 15560978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Adjuvants--essential components of new generation vaccines].
    Dzierzbicka K; Kołodziejczyk AM
    Postepy Biochem; 2006; 52(2):204-11. PubMed ID: 17078510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surface modified liposomes for nasal delivery of DNA vaccine.
    Khatri K; Goyal AK; Gupta PN; Mishra N; Mehta A; Vyas SP
    Vaccine; 2008 Apr; 26(18):2225-33. PubMed ID: 18396362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal immunization using biphasic lipid vesicles as delivery systems for OmlA bacterial protein antigen and CpG oligonucleotides adjuvant in a mouse model.
    Alcón VL; Baca-Estrada M; Vega-López MA; Willson P; Babiuk LA; Kumar P; Foldvari M
    J Pharm Pharmacol; 2005 Aug; 57(8):955-62. PubMed ID: 16102250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cationic liposomes as vaccine adjuvants.
    Christensen D; Korsholm KS; Rosenkrands I; Lindenstrøm T; Andersen P; Agger EM
    Expert Rev Vaccines; 2007 Oct; 6(5):785-96. PubMed ID: 17931158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leptospira immunoglobulin-like protein A variable region (LigAvar) incorporated in liposomes and PLGA microspheres produces a robust immune response correlating to protective immunity.
    Faisal SM; Yan W; McDonough SP; Chang YF
    Vaccine; 2009 Jan; 27(3):378-87. PubMed ID: 19022317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
    Joseph A; Itskovitz-Cooper N; Samira S; Flasterstein O; Eliyahu H; Simberg D; Goldwaser I; Barenholz Y; Kedar E
    Vaccine; 2006 May; 24(18):3990-4006. PubMed ID: 16516356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of thiol-reactive lipopeptide adjuvants. Incorporation into liposomes and study of their mitogenic effect on mouse splenocytes.
    Roth A; Espuelas S; Thumann C; Frisch B; Schuber F
    Bioconjug Chem; 2004; 15(3):541-53. PubMed ID: 15149182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators.
    Nordly P; Madsen HB; Nielsen HM; Foged C
    Expert Opin Drug Deliv; 2009 Jul; 6(7):657-72. PubMed ID: 19538037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study of cationic liposome and niosome-based adjuvant systems for protein subunit vaccines: characterisation, environmental scanning electron microscopy and immunisation studies in mice.
    Vangala A; Kirby D; Rosenkrands I; Agger EM; Andersen P; Perrie Y
    J Pharm Pharmacol; 2006 Jun; 58(6):787-99. PubMed ID: 16734980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Particulate delivery systems for animal vaccines.
    Scheerlinck JP; Greenwood DL
    Methods; 2006 Sep; 40(1):118-24. PubMed ID: 16997719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Archaeobacterial ether lipid liposomes (archaeosomes) as novel vaccine and drug delivery systems.
    Patel GB; Sprott GD
    Crit Rev Biotechnol; 1999; 19(4):317-57. PubMed ID: 10723627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liposomes act as stronger sub-unit vaccine adjuvants when compared to microspheres.
    Kirby DJ; Rosenkrands I; Agger EM; Andersen P; Coombes AG; Perrie Y
    J Drug Target; 2008 Aug; 16(7):543-54. PubMed ID: 18686124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-coding pDNA bearing immunostimulatory sequences co-entrapped with leishmanial antigens in cationic liposomes elicits almost complete protection against experimental visceral leishmaniasis in BALB/c mice.
    Mazumder S; Ravindran R; Banerjee A; Ali N
    Vaccine; 2007 Dec; 25(52):8771-81. PubMed ID: 18031874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surfactant vesicle-mediated delivery of DNA vaccines via the subcutaneous route.
    Perrie Y; Barralet JE; McNeil S; Vangala A
    Int J Pharm; 2004 Oct; 284(1-2):31-41. PubMed ID: 15454294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines.
    Patel GB; Zhou H; Ponce A; Chen W
    Vaccine; 2007 Dec; 25(51):8622-36. PubMed ID: 17959279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.